Background and aim: Serum fibrinogen and albumin are two important factors in systemic inflammation and these two factors are related to tumor progression. This study aimed to comprehensively reveal the prognostic value of the ratio of fibrinogen and albumin in malignant tumors. Methods: We systematically searched relevant studies in PubMed, Web of Science and Embase up to November 21, 2018. Hazard ratios (HRs) or odds ratio (ORs) for overall survival (OS)/disease-free survival (DFS), as well as relevant clinical data, were collected for analysis; all data analyses were performed by using STATA/SE 14. Results: Twelve cohort studies were included in this meta-analysis, with a total of 5,088 cases including 9 different kinds of tumors recruited. The pooled results showed that high albumin/fibrinogen ratio (FAR) and low fibrinogen/albumin ratio (AFR) were significantly associated with poor OS (HR=1.50, 95% CI: 1.30-1.70). Subgroup analyses for OS were also performed based on the disease type, detection method, follow-up time and treatment. Similarly, high FAR or low AFR indicated a worse DFS in cancer patients (HR=1.86; 95% CI: 1.41-2.31). In addition, high FAR or low AFR was statistically significant in relation to deeper tumor infiltration (OR=2.81, 95%CI: 1.67-4.72), positive lymph node metastasis (OR=1.57, 95%CI: 1.23-2.02) and distant metastasis (OR=2.30, 95% CI: 1.36-3.89) as well as advanced clinical stage (OR=2.02, 95% CI: 1.17-3.47).
Introduction
Inflammation has been convincingly considered as an important hallmark of cancer. 1, 2 It participates in the initiation, progression, and metastasis of human cancer. 3, 4 Tumorassociated inflammatory factors are closely related to the prognosis in cancer patients. 5, 6 Thereof, a series of inflammation-related index systems, including the systemic immune-inflammation index (SII), prognostic nutritional index (PNI) and C-reactive protein/albumin ratio (CAR), were reported as useful predictors in a variety of human tumors. [7] [8] [9] As novel inflammation-based markers, the combination with fibrinogen and albumin, namely, fibrinogen/albumin ratio (FAR) and albumin/fibrinogen ratio (AFR), were proposed and reported currently. The prognostic power of the ratio of fibrinogen and albumin was exhibited in several types of human cancers. [10] [11] [12] [13] For example, the patients with high FAR or low AFR had significantly worse survival than those with low FAR or high AFR in the breast, esophageal and gastric cancer; [10] [11] [12] while the ratio of fibrinogen and albumin was found to be no significant impact on overall survival in patients with colorectal cancer. 13 Besides, the findings on the relationship between the ratio of fibrinogen and albumin and clinicopathologic characteristics were reported but not inconsistent or even contradictory in these studies. Therefore, in order to provide a more accurate understanding of the prognostic significance of circulating FAR or AFR in cancer patients, we performed this systematic review and meta-analysis by pooling all those available data together. The links between the ratio of fibrinogen and albumin and clinicalpathological features were further investigated in this study.
Materials and methods

Search strategy and study selection
The current meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 14 PubMed, Embase, and Web of Science were comprehensively searched (up to November 21, 2018 ) with the following search terms: "albumin-to-fibrinogen or albumin/fibrinogen or fibrinogen-to-albumin or fibrinogen/albumin" combining with "cancer or tumor or malignancy or carcinoma or neoplasms". The search strategy is provided in the Supplementary material.
The inclusion criteria were as follows:
1. The correlation between serum AFR/FAR and overall survival (OS) or disease-free survival (DFS) of primary human malignancies were reported; 2. The assessment of hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) was available; 3. The full-articles were published in the English language.
The exclusion criteria were as follows:
1. Non-original articles (reviews, comments, editorials or conference abstracts, or case reports); 2. Articles without sufficient survival data for HRs; 3. Duplicated studies. In this study, we focused on two prognostic indicators, AFR and FAR. By definition, these two ratio values are opposite to each other. In this meta-analysis, the HR greater than 1 indicated a worse prognosis in subjects with high FAR or low AFR. We also assessed the quality of included studies, this method was detailed described in the article by Lin et al 15 .
Data extraction and quality assessment
It contains predefined nine items, a study could get a final score from the lowest 0 and the highest 9 after assessment.
Statistical analysis
All data analysis was performed using STATA/SE 14. 
Results
Finally, a total of 12 publications with 5,088 cases were included in this meta-analysis, [10] [11] [12] [13] [16] [17] [18] [19] [20] [21] [22] [23] the detailed process of study assessment is shown in Figure 1 . All these enrolled studies were retrospective design, and they were written in the English language and published in 2017 and 2018. Among them, eleven studies were carried out in P.R. China, and one in Korea. A total of nine different kinds of human malignant tumors were investigated: breast cancer (BC), esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gallbladder cancer (GBC), chronic lymphocytic leukemia (CLL), and soft tissue sarcoma (STS). Among those studies, seven articles reported the relationship between the AFR and OS, and five studies investigated the association between the FAR and prognosis of OS. Two studies focused on the prognostic value of AFR/FAR on DFS. The quality of all included studies was good with a median score of 8 (range 7-9, Figure 2 , Table S1 ). Table 2 .
The ratio of fibrinogen and albumin and DFS
Only two studies reported the relationship between the ratio of fibrinogen and albumin and DFS, no significant heterogeneity was found among studies (I 2 =0.0%, P=0.707), a fixed effects model was used to analyze the pooled HRs. As shown in Figure 4 , the combined results indicated that the patients with high FAR or low AFR had a worse DFS (HR=1.86; 95% CI: 1.41-2.31; P<0.001).
The ratio of fibrinogen and albumin and clinicopathological features
The clinical relevance of the ratio of fibrinogen and albumin in tumor cases is presented in Overall (I-squared = 0.0%, P=0.707) Figure 4 Pooled results for the correlation between the ratio of fibrinogen and albumin and DFS in cancer patients. Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, confidence interval. 
Publication bias
Begg's funnel plot was symmetrical ( Figure 5 ) and Begg's test had a value of 0.086 (P>0.05), which suggestive of the absence of publication bias.
Sensitivity analysis
Sensitivity analysis indicated that the overall results in this meta-analysis were stable and reliable ( Figure 6 ).
Discussion
The relationships between FAR and AFR and prognosis were reported in previous studies, however, their prognostic and clinical-pathological values in cancer patients remains undetermined. Hence, we performed this metaanalysis for the first time to figure out the prognostic impact of this scoring system in cancers. We included 12 cohort studies with a total of 5088 cancer cases, and 9 different kinds of human malignancies were enrolled. By
1.5
Begg's funnel plot with pseudo 95% confidence limits pooling all the available OS data from multivariate analyses, we found that patients with high FAR or low AFR had a significantly lower OS rate than those with low FAR or high AFR (HR=1.50, 95% CI: 1.30-1.70; p<0.001), and moreover, high FAR or low AFR was found to be an independent factor of unfavorable OS in patients with GI cancers or non-GI cancers, and there was clear evidence that high FAR and low AFR could be a significant predictor in long-term overall survival rate (≥5 years) or short-term survival rate (<5 years) between the two groups. In addition, the ratio of fibrinogen and albumin might be an important predictor for DFS in cancers (HR=1.86; 95% CI: 1.41-2.31; p<0.001).
Similarly, the significant associations between clinicopathological features and this scoring system were also found in tumor infiltration (p<0.001), lymph node metastasis (p<0.001), distant metastasis (p=0.002) and clinical stage (p=0.011).
Although the specific mechanism for the roles of this scoring system predicting cancer progression and prognosis remains incompletely understood, there are some potential explanations for this. Fibrinogen level was frequently observed elevated in serum of the cancer patients and hyper-fibrinogenemia was demonstrated to be related to unfavorable prognoses in multiple tumors, including liver cancer, lung cancer, esophageal cancer and urinary tract urothelial carcinoma. [24] [25] [26] [27] Fibrinogen is an important factor involved in hemostasis, and the coagulation system is often abnormally activated in cancer patients, 2, 28, 29 and it could possess anti-cancer properties as a compound with sodium selenite. 6 And as an acute-phase-response protein, fibrinogen could also reflect the statue of the systemic inflammatory response, which was closely related to carcinogenesis. [30] [31] [32] In addition, fibrinogen could regulate tumor cell growth as an extracellular matrix protein by binding to multiple growth factors, [33] [34] [35] and enhance cell migration, invasion, and metastasis involving epithelialmesenchymal transition. [36] [37] [38] Fibrinogen also played a vital role in angiogenesis, which closely participated in the progression of cancer. [39] [40] [41] [42] On the other side, albumin has been considered as an indicator that could objectively reflect the nutritional status, low serum albumin level often heralds malnutrition, and indicates weakened immunity in subjects. [43] [44] [45] In addition, albumin is also a crucial factor that involved in the systemic inflammatory response, low concentration of albumin was shown to be related to the enhancement of inflammatory response to cancers and then release of a series of cancer-related cytokines, which could contribute to tumor development. [46] [47] [48] Furthermore, clinical studies showed that there was a significant association between albumin level and prognosis in various types of tumors, the low pretreatment serum albumin level yielded an unfavorable prognosis in cancers. [49] [50] [51] Several limitations in our meta-analysis should be carefully considered. First, the number of cohort studies that included was relatively small and the total sample size was also limited. Second, all included studies were carried out in two Asian countries, this might affect the applicability of our conclusions, more studies with different populations are required in the future. Third, we only included full-text articles published in the English language. Fourth, the prognostic roles of the ratio of fibrinogen and albumin in specific cancers were not investigated for the lack of sufficient data. Fifth, only two studies reported the data of DFS rate, and as a result, their impacts on DFS should be further confirmed. Last but not least, the cut-off of this scoring system varied among studies. As the limitations mentioned above, further researches should be embraced to verify and update our findings.
In summary, this meta-analysis systematically assessed the prognostic impact of the novel inflammation-based prognostic scores (FAR and AFR) on cancer patients. We found that high FAR and low AFR indicated worse prognosis and adverse clinical progression in tumors. And the prognostic validity of AFR and FAR should be globally checked for various cancer types, as these parameters can be easily obtained in a cheap and non-invasive manner, this might lead to their incorporation in official cancer management guidelines.
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